02161nas a2200241   4500000000100000008004100001260004100042653001900083653002200102653001200124653002000136653001800156100001800174700001100192700001700203700001100220245008500231856006500316300001000381490000700391520149600398022002501894       2026                            d  c05/2026bNepal Journals Online (JOL)10achronic ulcers10aNon healing ulcer10aLeprosy10aTopical insulin10aTrophic ulcer1 aRatnaparkhi A1 aFale P1 aRahangdale V1 aUnni M00aTopical Insulin: A Game Changer for Non-Healing Leprosy Ulcers – A Case Series  uhttps://nepjol.info/index.php/NJDVL/article/view/84140/71129  a54-570 v243 a<jats:p>Leprosy, caused by Mycobacterium leprae, frequently leads to neuropathic trophic ulcers and ulcerative lesions associated with type II lepra reactions. These ulcers are difficult to treat due to sensory loss, repeated trauma, and poor vascularity, often responding inadequately to conventional therapies. Topical insulin has recently gained attention for its potential to enhance local wound healing by stimulating angiogenesis, collagen deposition, and re-epithelialization without systemic adverse effects. This case series included five male patients with Hansen’s disease who presented with chronic trophic ulcers or ulcerative lesions of lepra reaction. A solution of 0.1 ml Actrapid insulin diluted with 0.9 ml normal saline was irrigated directly to the ulcer surface twice daily and covered with sterile gauze for five minutes. The intervention was continued for four to six weeks. Ulcer size, depth, tissue quality, and granulation were assessed clinically and documented photographically at baseline and follow-up. All patients showed significant improvement within two weeks, with marked reduction in ulcer dimensions and healthy granulation tissue formation. Complete epithelization was achieved in four to six weeks. No local or systemic adverse effects were observed, and compliance was excellent. Topical insulin is a safe, economical, and effective therapeutic option for leprosy-associated ulcers, meriting further evaluation in larger controlled studies.</jats:p>  a2091-167X, 2091-0231